Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 17, 2023

Patritumab Deruxtecan for Untreated HR+/HER2− Early Breast Cancer



Additional Info

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study
ESMO Open 2023 May 19;[EPub Ahead of Print], M Oliveira, C Falato, JM Cejalvo, MM Vila, P Tolosa, FJ Salvador-Bofill, J Cruz, M Arumi, AM Luna, JA Guerra, M Vidal, O Martínez-Sáez, L Paré, B González-Farré, E Sanfeliu, E Ciruelos, M Espinosa-Bravo, S Pernas, Y Izarzugaza, S Esker, PD Fan, P Parul, A Santhanagopal, D Sellami, G Villacampa, JM Ferrero-Cafiero, T Pascual, A Prat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading